We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report.
- Authors
Ikuko Nakamura; Jun-ichi Oyama; Hiroshi Komoda; Aya Shiraki; Yoshiko Sakamoto; Isao Taguchi; Atsushi Hiwatashi; Aiko Komatsu; Sho-ichi Yamagishi; Teruo Inoue; Koichi Node; Masayoshi Takeuchi
- Abstract
Background The purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus. Methods and results Thirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer- AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE). Conclusions Glimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.
- Subjects
ADVANCED glycation end-products; CYTOKINES; CHEMOKINES; GROWTH factors; GLYCERALDEHYDEPHOSPHATE dehydrogenase
- Publication
Cardiovascular Diabetology, 2014, Vol 13, Issue 1, p3
- ISSN
1475-2840
- Publication type
Article
- DOI
10.1186/1475-2840-13-15